Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at risk.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily. For patients with healed erosive esophagitis, a dose of 20 mg orally once daily may be sufficient.
* **NSAID-Associated Gastric Ulcers:** 40 mg orally once daily. Duration of therapy is typically up to 8 weeks.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response and need. Doses up to 240 mg intravenously daily have been used.
## Pediatric Dosing
Dosing varies significantly by indication and age/weight. Consult specific pediatric guidelines or product labeling. Generally:
* **Erosive Esophagitis (5 to 16 years):** 20 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (older than 16 years):** 40 mg orally once daily for up to 8 weeks.
* Higher doses may be used for pathological hypersecretory conditions under specialist supervision.
## Dose Adjustments
No dose adjustment is generally required for renal impairment.
For hepatic impairment, consider reducing the dose of pantoprazole to 20 mg orally once daily.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, systemic lupus erythematosus (new or exacerbation).
## Key Drug Interactions
* **Drugs Dependent on Gastric pH:** PPIs can decrease absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, iron salts, vitamin B12).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider dose reduction or interruption of pantoprazole.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel (reduced efficacy), though clinical significance is debated.
* **HIV Protease Inhibitors:** Concurrent use may reduce absorption of certain HIV protease inhibitors.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Monitor serum magnesium levels, especially with prolonged use (typically > 3 months), and consider supplementation.
* Monitor for bone fracture risk, especially with long-term use and in patients with risk factors.
* Monitor for signs of vitamin B12 deficiency with long-term therapy.
* Monitor for new or worsening symptoms of systemic lupus erythematosus.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* Intravenous administration requires reconstitution and dilution; follow specific guidelines.
* Long-term use of PPIs is associated with potential risks (fractures, hypomagnesemia, B12 deficiency, C. difficile infection); use the lowest effective dose for the shortest duration necessary.
* Discontinuation of PPIs may lead to rebound acid hypersecretion; consider gradual tapering.
---
*Disclaimer: This information is intended for healthcare professionals. Always verify current prescribing information and consult with a qualified healthcare provider before making any treatment decisions.*
